EpiBiologics launches with $50 million and goal to be extracellular degradation leader

Protein degradation company EpiBiologics has launched with $50 million in Series A funding.

The company’s technology platform is based on the scientific work of EpiBiologics’ co-founder, the antibody engineer Jim Wells of the University of California, San Francisco (UCSF), and the platform intellectual property has been exclusively licensed from UCSF.

"The current financing will enable us to expand and validate the platform, advance our pipeline of drug candidates, and further build our talented team of scientists and protein engineers"Protein degradation technologies are of high interest to the medical community because of their potential to attack disease targets that have been historically difficult to drug. However, companies pursuing these approaches have focused primarily on intracellular proteins.